Sangamo Therapeutics, Inc. (SGMO) News

Sangamo Therapeutics, Inc. (SGMO): $1.66

-0.04 (-2.35%)

POWR Rating

Component Grades













Add SGMO to Watchlist
Sign Up

Industry: Biotech


of 382

in industry

Filter SGMO News Items

SGMO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SGMO News Highlights

  • For SGMO, its 30 day story count is now at 7.
  • Over the past 28 days, the trend for SGMO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about SGMO are GENE, AG and CELL.

Latest SGMO News From Around the Web

Below are the latest news stories about SANGAMO THERAPEUTICS INC that investors may wish to consider to help them evaluate SGMO as an investment opportunity.

The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership

Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial.

Yahoo | March 23, 2023

Sangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | March 21, 2023

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo

Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. The Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategi

Yahoo | March 20, 2023

10 Companies That Had Tons of Money in SVB When It Collapsed

Silicon Valley Bank is gone but its clients are still here.

Samuel O'Brient on InvestorPlace | March 13, 2023

Sangamo (SGMO) Loses -24.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sangamo (SGMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | March 10, 2023

In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions

Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence...

Yahoo | February 25, 2023

Sickle-cell gene therapy developer stops program, cuts half of staff

Gene therapy offered hope for thousands of sickle cell disease patients. Now many are ending their programs.

Yahoo | February 23, 2023

Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of α-Gal A activity, sustained for over two years for the patient with the longest follow-up. All five patients who began the dose escalation pha

Yahoo | February 23, 2023

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2023

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results


Yahoo | February 22, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.72 seconds.